Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Judge throws book at Daniel Chapter One

This article was originally published in The Tan Sheet

Executive Summary

An administrative judge upholds the Federal Trade Commission's charges that supplement marketer Daniel Chapter One falsely advertised its shark cartilage and herbal formulations prevent, treat and cure cancer. The judge found the firm could not substantiate its claims with reliable scientific evidence and ordered the company to stop making false claims. FTC charged Daniel Chapter One with deceptive advertising in 2008 in an enforcement sweep that charged 11 firms with marketing false cancer remedies (1"The Tan Sheet" Sept. 22, 2008)

You may also be interested in...



FTC affirms cancer cures case ruling

Daniel Chapter One must notify customers it made deceptive and unsubstantiated cancer cure claims for its herbal products after failing in its appeal of an administrative law judge's ruling to uphold Federal Trade Commission charges. The commission's unanimous 1opinion, announced Dec. 24, says respondents Daniel Chapter One and James Feijo "lacked a reasonable basis to substantiate" claims their products BioShark, 7 Herb Formula and others inhibit tumor growth and are effective cancer treatments. Like other companies charged in FTC's 2008 enforcement sweep against bogus cancer cure claims, Providence, R.I.-based Daniel Chapter One is enjoined from making such claims without supporting scientific evidence (2"The Tan Sheet" Aug. 17, 2009, In Brief)

Cancer Claims Continue Attracting Federal Enforcement Actions

Herbal and supplement products allegedly making deceptive cancer cure claims prompted the Federal Trade Commission to file complaints against 11 firms, including five that rejected settlement offers and are contesting the complaints

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel